Fundz
Back to SEC Filings
10-QHIGH RiskDETERIORATING

OS Therapies Inc

ostherapies.com
Filed: May 18, 2026 CIK: 0001795091Healthcare
View original filing on SEC.gov

AI Executive Summary

AI-powered analysis of 10-Q filing content

OS Therapies shows severe financial deterioration with net losses increasing 168% year-over-year to $10.4M in Q1 2026. The company is technically insolvent with stockholders' deficit expanding to -$10.8M and current liabilities of $17M far exceeding cash of $918K, creating immediate liquidity concerns.

Red Flags Detected (7)

Stockholders' deficit increased 78% from -$6.1M to -$10.8M in one quarter

Current liabilities of $17M vs only $918K cash - severe liquidity crisis

Net loss increased 168% year-over-year from $3.9M to $10.4M

4 more red flags detected

Key Takeaways

Company faces immediate bankruptcy risk with current liabilities 18x exceeding cash

Massive R&D spending increase suggests late-stage clinical trials but with extreme financial risk

2 more takeaways

Filing Overview

Form TypeQuarterly Report (10-Q)
Filing DateMay 18, 2026
Risk LevelHIGH
TrendDETERIORATING
AI Confidence95%
Red Flags7

What This Means

High Risk Filing: This company is showing signs of financial stress or significant operational challenges.

Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.

Quarterly Report: Interim filing with unaudited financial data for the quarter.

View Full Filing on SEC.govBrowse More Filings